•  
• Tweet
•  
•  
•        Print
•  
•        Email
•  
•         Track Keywords

“A rate cut in Europe, far-reaching reforms announced in China, and generally positive economic data contributed to a third month of rising equity prices," says Sol Waksman, founder and president of BarclayHedge.

Sixteen of Barclay’s 18 hedge fund indices had gains in November. The Barclay Healthcare & Biotechnology Index jumped 3.05%, Distressed Securities gained 1.71%, Global Macro added 1.68%, Equity Long Bias was up 1.55%, European Equities gained 1.37%, and Pacific Rim Equities were up 1.24%.

“In spite of a dismal launch that raised concerns about Obamacare’s longer term success, healthcare was the top performing sector in November as well as year to date," says Waksman.

The Healthcare & Biotechnology Index has gained 25.66% in 2013, Pacific Rim Equities are up 20.63%, Equity Long Bias Index has returned 19.23%, Distressed Securities have gained 15.89%, and Equity Long/Short is up 12.10%.

On the losing side, the Equity Short Bias Index was down 2.01% in November, and Emerging Markets lost 0.53%.

The Equity Short Bias Index is now down 25.32% in 2013, surpassing last year’s record loss of 24.12%. All other hedge fund strategies tracked by BarclayHedge have gains year to date.

The Barclay Fund of Funds Index gained 1.01% in November, and is up 7.22% after 11 months in 2013.

BarclayHedge

Press Release

BM